Biomarker Study for Selecting Neoadjuvant Chemotherapy Regimens Based on Prognostic Prediction Using Gastric Cancer Biopsy Specimens from a Phase II Randomized Controlled Trial
Anticancer Research · 2024
DOI: 10.21873/anticanres.17320 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Anticancer Research, 2024. Verfasst von Takashi Oshima und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan; oshimat@kcch.jp. Hauptthemen laut MEDLINE: Stomach Neoplasms, Biomarkers, Tumor, Neoadjuvant Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND/AIM: The randomized phase II COMPASS trial revealed that neither the regimen nor the number of courses of preoperative neoadjuvant chemotherapy (NAC) for locally advanced gastric cancer (GC) significantly influence overall survival (OS). However, the impact of NAC regimens on OS may vary from patient to patient. The aim of this study was to identify biomarkers that can predict more appropriate individualized NAC regimens for improved prognosis using biopsy specimens from the COMPASS trial. PATIENTS AND METHODS: RNA was extracted from endoscopic biopsy specimens of primary tumors obtained prior to NAC and real-time PCR analysis of 127 genes was conducted to identify those significantly affecting survival in the context of specific NAC regimens. RESULTS: THBS1, MSI1, and IGF2BP3 were identified as significant factors for stratifying survival among different NAC regimens, with statistically significantly interaction p values. Immunohistochemical analysis confirmed that the protein levels of THBS1, MSI1, and IGF2BP3 strongly correlated with their gene expression levels, validating these proteins as reliable biomarkers. CONCLUSION: This study effectively identified THBS1, MSI1, and IGF2BP3 as promising biomarkers for personalizing NAC regimens in patients with locally advanced GC. By tailoring NAC based on these biomarkers, it is possible to enhance survival outcomes and advance personalized treatment strategies. The findings underscore the potential for incorporating biomarker-guided approaches into clinical trials, aiming to refine and optimize NAC regimens for improved patient-specific treatment efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan; oshimat@kcch.jp.
- Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
- Kanagawa Cancer Center Research Institute, Yokohama, Japan.
- Department of Biomedical Statics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Graduate School of Environmental and Life Science, Okayama University, Okayama, Japan.
- Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Zitieren
APA
Oshima, T., Yoshikawa, T., Miyagi, Y., Morita, S., Yamamoto, M., Tanabe, K., Nishikawa, K., Ito, Y., Matsui, T., Kimura, Y., Aoyama, T., Ogata, T., Cho, H., Tsuburaya, A., & Sakamoto, J. (2024). Biomarker Study for Selecting Neoadjuvant Chemotherapy Regimens Based on Prognostic Prediction Using Gastric Cancer Biopsy Specimens from a Phase II Randomized Controlled Trial. Anticancer Research. https://doi.org/10.21873/anticanres.17320
Vancouver
Oshima T, Yoshikawa T, Miyagi Y, Morita S, Yamamoto M, Tanabe K, et al. Biomarker Study for Selecting Neoadjuvant Chemotherapy Regimens Based on Prognostic Prediction Using Gastric Cancer Biopsy Specimens from a Phase II Randomized Controlled Trial. Anticancer Research. 2024. doi:10.21873/anticanres.17320
BibTeX
@article{Oshima2024,
author = {Oshima, Takashi and Yoshikawa, Takaki and Miyagi, Yohei and Morita, Satoshi and Yamamoto, Michio and Tanabe, Kazuaki and Nishikawa, Kazuhiro and Ito, Yuichi and Matsui, Takanori and Kimura, Yutaka and Aoyama, Toru and Ogata, Takashi and Cho, Haruhiko and Tsuburaya, Akira and Sakamoto, Junichi},
title = {Biomarker Study for Selecting Neoadjuvant Chemotherapy Regimens Based on Prognostic Prediction Using Gastric Cancer Biopsy Specimens from a Phase II Randomized Controlled Trial},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17320}
}
EUVIMED